A small but rapidly growing number of U.S. adolescents began treatment with Novo Nordisk's <NOVOb.CO> weight-loss drug Wegovy last year, a powerful new tool to address.
Healthcare costs from a rise in the number of primary schoolchildren who became overweight and obese during the pandemic could top £800 million, research found.